Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2019 2
2020 1
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) randomised clinical trial: study protocol.
Daneman N, Rishu AH, Pinto RL, Arabi YM, Cook DJ, Hall R, McGuinness S, Muscedere J, Parke R, Reynolds S, Rogers B, Shehabi Y, Fowler RA; Canadian Critical Care Trials Group. Daneman N, et al. BMJ Open. 2020 May 11;10(5):e038300. doi: 10.1136/bmjopen-2020-038300. BMJ Open. 2020. PMID: 32398341 Free PMC article. Clinical Trial.
INTRODUCTION: Bloodstream infections are a leading cause of mortality and morbidity; the duration of treatment for these infections is understudied. ...Secondary outcomes include hospital and intensive care unit (ICU) mortality, relapse r …
INTRODUCTION: Bloodstream infections are a leading cause of mortality and morbidity; the duration of treatment for thes …
Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics: A Prospective Cohort Study.
Ianiro G, Murri R, Sciumè GD, Impagnatiello M, Masucci L, Ford AC, Law GR, Tilg H, Sanguinetti M, Cauda R, Gasbarrini A, Fantoni M, Cammarota G. Ianiro G, et al. Ann Intern Med. 2019 Nov 19;171(10):695-702. doi: 10.7326/M18-3635. Epub 2019 Nov 5. Ann Intern Med. 2019. PMID: 31683278
BACKGROUND: Clostridioides difficile infection (CDI) is a risk factor for bloodstream infection (BSI). ...OBJECTIVE: To assess incidence of primary BSI in patients with recurrent CDI treated with FMT versus antibiotics. ...
BACKGROUND: Clostridioides difficile infection (CDI) is a risk factor for bloodstream infection (BSI). .. …
The outcomes of Clostridioides difficile infection in inpatient liver transplant population.
Amjad W, Qureshi W, Malik A, Singh R, Jafri SM. Amjad W, et al. Transpl Infect Dis. 2022 Feb;24(1):e13750. doi: 10.1111/tid.13750. Epub 2021 Nov 3. Transpl Infect Dis. 2022. PMID: 34695277
Our aim is to determine the inpatient outcomes of liver transplant patients with Clostridioides difficile infection (CDI) and trends in the last few years. ...CONCLUSION: CDI in post-liver transplant patients was associated with higher mortal
Our aim is to determine the inpatient outcomes of liver transplant patients with Clostridioides difficile infection
Prolonged Clostridium difficile Infection May Be Associated With Vitamin D Deficiency.
Wong KK, Lee R, Watkins RR, Haller N. Wong KK, et al. JPEN J Parenter Enteral Nutr. 2016 Jul;40(5):682-7. doi: 10.1177/0148607114568121. Epub 2015 Jan 26. JPEN J Parenter Enteral Nutr. 2016. PMID: 25623479
BACKGROUND: Clostridium difficile infection (CDI) is one of the leading causes of hospital-acquired infections, creating a financial burden for the U.S. healthcare system. ...There were no differences in CDI recurrence, length
BACKGROUND: Clostridium difficile infection (CDI) is one of the leading causes of hospital-acquired infection
Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial.
Thorlacius-Ussing L, Andersen CØ, Frimodt-Møller N, Knudsen IJD, Lundgren J, Benfield TL. Thorlacius-Ussing L, et al. Trials. 2019 May 2;20(1):250. doi: 10.1186/s13063-019-3357-9. Trials. 2019. PMID: 31046810 Free PMC article.
However, evidence to support these treatment recommendations remains scarce. Patients with uncomplicated SAB are known to have a low of risk of recurrence and death. ...Secondary outcomes include the prevalence of severe adverse effects, in particular secondary i
However, evidence to support these treatment recommendations remains scarce. Patients with uncomplicated SAB are known to have a low …